WAVEMAN · COMPANY

ENTX · Entera Bio Ltd.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

ENTX

Name: Entera Bio Ltd. (ENTX) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Entera Bio Ltd.

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001638097

ACTIVIST 13D☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

15 funds added or opened last quarter

below 74% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

0.7% of shares outstanding short · 1.0 days to cover · settled 2026-07-31

below 76% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

BIOTECHNOLOGY VALUE FUND L P disclosed a 5%+ stake (5.3%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +51.5%

+51.5%12M

INSIDER BUY13D/G STAKE

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

An activist crossed the 5% line with declared intent.

The record shows 15 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Entera Bio Ltd. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Germano Geno J

Director

BUY

2026-03-09

20,000.0

$26.0K

Ellis Sean

Director

BUY

2026-03-05

10,000.0

$12.3K

Rubin Steven D

Director

BUY

2026-02-12

5,000.0

$7.5K

Taitel Haya

Director

BUY

2026-02-10

7,500.0

$11.1K

Germano Geno J

Director

BUY

2026-02-10

20,000.0

$29.8K

36 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 31 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Knoll Capital Management, LLC

5,881,879.0 sh

$10.4M

BVF INC/IL

2,425,000.0 sh

$4.3M

Siren, L.L.C.

736,457.0 sh

$1.3M

RENAISSANCE TECHNOLOGIES LLC

368,847.0 sh

$652.9K

Parkman Healthcare Partners LLC

274,497.0 sh

$485.9K

5%+ owners

13D = intent to influence · 13G = passive

BIOTECHNOLOGY VALUE FUND L P

ACTIVIST 13D · 2026-08-04

5.3%

BVF I GP LLC

ACTIVIST 13D · 2026-08-04

5.3%

BIOTECHNOLOGY VALUE FUND II LP

ACTIVIST 13D · 2026-08-04

3.9%

BVF II GP LLC

ACTIVIST 13D · 2026-08-04

3.9%

Biotechnology Value Trading Fund OS LP

ACTIVIST 13D · 2026-08-04

0.7%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Clinical pipeline

ClinicalTrials.gov · 1 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

0 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Executive pay vs shareholder return · Miranda Toledano

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$1.5M

$1.4M

$518.0K

+123%

—

2024

$1.1M

$2.2M

$485.0K

+112%

—

2023

$950.0K

$483.0K

$385.0K

-79%

—

2022

$679.0K

$761.0K

$502.0K

-74%

—

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP